BridgeBio Neutral Stance From Citi Shakes ATTR-CM Outlook
Citi initiates BridgeBio at Neutral, signaling caution on ATTR-CM growth despite a strong near-term ramp. The move ad...
Citi initiates BridgeBio at Neutral, signaling caution on ATTR-CM growth despite a strong near-term ramp. The move ad...
BridgeBio's Q1 2026 earnings narrative is more than quarterly numbers—it's a roadmap for the year ahead. This guide e...